Here, we demonstrated the capabilities of the IGF1R model by developing cell line-specific models that used proteomics data available from diverse human cancer cell lines, including leukemias, melanomas, and breast, colon, prostate, renal, lung, bone, central nervous system, cervical, and ovarian cancers. This evidence concerns the gene IGF1R and ovarian carcinoma.